Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda Mulls Taking Stab at Generic Biz in Japan via ASKA
September 6, 2013
- General Logistics Companies Increasing Their Investment in Field of Drug Distribution; Opening More Specialized Warehouses
September 6, 2013
- Edoxaban Shows Non-Inferiority to Warfarin for VTE: Daiichi Sankyo
September 6, 2013
- Will Once-weekly Formulations and New Products Help GLP-1 Receptor Agonists Break Out of Their Slump?
September 6, 2013
- Teva Japan to Pursue High-Value-Added Generics, Eyes Partnerships with Japanese Companies: Chairman Krinsky
September 5, 2013
- Teva Pharma Japan Aims for the Top in Japan Generic Market by 2018: President
September 5, 2013
- Kyowa Kirin Ties Up with Ultragenyx for XLH Treatment KRN23
September 5, 2013
- ASKA to Launch Generic Biz Unit; Takeda’s Yonezawa to Take Helm
September 4, 2013
- Otsuka Paid 20 Billion Yen to Healthcare Professionals in FY2012, 5.4 Billion Yen for Information Provisioning
September 4, 2013
- Fuji Yakuhin, Sanwa Kagaku Launch Gout and Hyperuricemia Treatments Topiloric/Uriadec
September 4, 2013
- President or Head of General Medicine OK’ed Research Grants to 2 Universities: Novartis Exec
September 3, 2013
- Astellas, MSD to Tie Up for SGLT-2 Inhibitor Ipragliflozin
September 3, 2013
- Chugai, Taisho Toyama to Offer Compliance Advantages with Once-Monthly Bonviva
September 3, 2013
- MTPC’s SGLT-2 Inhibitor Canagliflozin Now No. 1 in Prescription Share in US, Overtaking Januvia
September 3, 2013
- Astellas Paid 19.3 Billion Yen to Healthcare Professionals, 7.1 Billion Yen for Information Provisioning in FY2012
September 3, 2013
- Takeda’s OBLEAN Near-Certain to Debut as Japan’s 1st Anti-Obesity Drug in 20 Years
September 2, 2013
- Daiichi Sankyo Provided 36.6 Billion Yen to Physicians, Medical Institutions in FY2012, 22.7 Billion Yen for R&D
September 2, 2013
- US FDA Requests Additional Data for Tolvaptan for Treatment of ADPKD: Otsuka
September 2, 2013
- Orphan Drug Wholesaler S.D. Next to Swing into Black in FY2015 with Tailored Distribution Services: Pres.
August 30, 2013
- WHO Grants Prequalification to Eisai for Lymphatic Filariasis Treatment
August 30, 2013
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…